Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Taysha Gene Therapies, Inc. - Common Stock (NQ:TSHA)

4.175 +0.165 (+4.11%)
Streaming Delayed Price Updated: 10:44 AM EST, Nov 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Taysha Gene Therapies, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Taysha Gene Therapies Inc (NASDAQ:TSHA) Stock Slumps on Q3 Revenue Miss Despite Key Regulatory Win for TSHA-102 ↗
Taysha Gene Therapies stock fell after Q3 results, with a revenue miss overshadowing positive FDA Breakthrough Therapy designation for its Rett syndrome drug. 
Via Chartmill
News headline image
Earnings Scheduled For November 4, 2025 ↗
 
Via Benzinga
News headline image
Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Is Taysha Gene Therapies Stock Falling Friday? ↗
Taysha Gene Therapies shares fall after regaining full rights to Rett syndrome drug TSHA-102 and finalizing FDA alignment for pivotal trial. 
Via Benzinga
News headline image
Taysha Gene Therapies Stock Soars To 3-Year High After FDA Boost — Wall Street Calls Rett Drug ‘Derisked’ And Ahead Of Rivals ↗
Taysha shares jumped after analysts at Baird, H.C. Wainwright, and Needham turned bullish, citing FDA alignment and an expedited approval path for its Rett syndrome therapy. 
Via Stocktwits
News headline image
What's Next: Taysha Gene Therapies's Earnings Preview ↗
 
Via Benzinga
News headline image
Where Taysha Gene Therapies Stands With Analysts ↗
 
Via Benzinga
News headline image
Healthcare Sector Shines Amidst Market Turbulence, Bolstering S&P 500 Resilience
On October 2, 2025, the Healthcare sector emerged as a beacon of stability and growth within the S&P 500, delivering a robust positive performance that significantly contributed to the broader market's... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
Demystifying Taysha Gene Therapies: Insights From 6 Analyst Reviews ↗
 
Via Benzinga
News headline image
Discover the most active stocks in Thursday's session. ↗
These stocks are making the most noise in today's session. Stay tuned for the latest updates! 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Here are the top movers in Thursday's session. ↗
Intrigued by the market activity in the middle of the day on Thursday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
News headline image
Taysha Gene Therapies, Canaan, Ondas Holdings And Other Big Stocks Moving Higher On Thursday ↗
U.S. stocks were mixed, with the Dow Jones index falling more than 50 points on Thursday. 
Via Benzinga
Topics Stocks
News headline image
Taysha Gene Therapies Stock Soars After FDA Grants Breakthrough Therapy Designation To Gene Therapy ↗
Taysha also announced that it has finalized alignment with the FDA on the protocol for the trial intended to support its application for approval of TSHA-102. 
Via Stocktwits
News headline image
Which stocks are gapping on Thursday? ↗
The market is buzzing with gapping stocks on Thursday. Let's uncover which stocks are experiencing notable gaps during today's session. 
Via Chartmill
News headline image
Top 2 Health Care Stocks That May Keep You Up At Night This Month ↗
 
Via Benzinga
News headline image
What's Driving the Market Sentiment Around Taysha Gene Therapies? ↗
 
Via Benzinga
News headline image
Is Taysha Gene Therapies Gaining or Losing Market Support? ↗
 
Via Benzinga
News headline image
A Glimpse Into The Expert Outlook On Taysha Gene Therapies Through 11 Analysts ↗
 
Via Benzinga
News headline image
Beyond The Numbers: 10 Analysts Discuss Taysha Gene Therapies Stock ↗
 
Via Benzinga
News headline image
Retail Buzz Surges Around Taysha Gene Therapies After Positive Rett Syndrome Trial Data ↗
Canaccord Genuity raised its price target on Taysha Gene Therapies to $11 from $9, citing improved clinical data and increased confidence in the company’s TSHA-102 program. 
Via Stocktwits
News headline image
Why Is Taysha Gene Therapies Stock Trading Higher On Thursday? ↗
Taysha shared the TSHA-102 trial plan after FDA alignment and reported 100% milestone gains with no serious adverse events in Rett syndrome patients. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 12, 2025 ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Get insights into the top gainers and losers of Wednesday's after-hours session. ↗
As the regular session of the US market on Wednesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment. 
Via Chartmill
News headline image
Expert Outlook: Taysha Gene Therapies Through The Eyes Of 6 Analysts ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 15, 2025 ↗
 
Via Benzinga
News headline image
Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation ↗
FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biotech stock losses and analyst concerns. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.